Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • TA319
  • Published: 
Download guidance (PDF)

7 Review of guidance

7.1 The guidance for this technology will be considered for review in June 2017. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
July 2014